NCT03648359Enrolling by invitation
Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
To investigate whether multiparametric MRI (mp-MRI) in patients with low-risk prostate cancer can improve the selection of patients suitable for Active Surveillance and have a relevance in the ongoing monitoring
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 19 Jan 2016
- Start date
- 1 May 2020
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Herlev Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT03648359
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 May 2020 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Metastatic prostate cancer
- Prostate cancer treatment
- Known allergic reaction to Gadolinium-based MRI contrast agent
- Psychiatric disorders
Lab values
- Impaired renal function with GFR \< 30 ml / min
Age
- Age under 18 year
Other
- No mp-MRI data present
- Prostate biopsy during the last 21 days
- pacemaker
- Magnetic metal residues in the body
- Claustrophobia
Who the study is looking for
- Patients with low risk localized prostate cancer enrolled in active surveillance
Age in the registry: 18 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Urology, Herlev University Hospital Herlev Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.